Paradigm Genetics, Inc. (Nasdaq: PDGM) and LION bioscience AG (Nasdaq: LEON, Neuer Markt: 504 350, LIO) announced that they have expanded their five-year strategic alliance. The alliance was first initiated in January 2000, to co-develop and co-market MetaTraceTM, a metabolic profiling database. Under the terms of the expanded agreement, biochemical data will be added to the MetaTraceTM database enabling pharmaceutical research and discovery based on metabolic information. Financial terms have not been disclosed. www.paragen.com
CED News
« Gartner Group Ranks Relativity Technologies as the Leader in 2 Magic Quadrants | Main | Amphora Establishes Corporate Headquarters In Research Triangle Park »